Key result
Bone scintigraphy yields ~97% sensitivity and ~96% specificity for diagnosing ATTR-CM.
Why the study?
ATTR-CM is an under-recognised cause of heart failure with preserved ejection fraction in older adults, and the availability of disease-modifying therapies has made early and accurate identification, staging, and response assessment with nuclear imaging clinically important.
Does advanced nuclear imaging (bone-avid tracer scintigraphy, SPECT/CT, and amyloid-targeted PET) improve the diagnosis, staging, and therapy monitoring in patients with transthyretin amyloid cardiomyopathy (ATTR-CM)?
Does advanced nuclear imaging (bone-avid tracer scintigraphy, SPECT/CT, and amyloid-targeted PET) improve the diagnosis, staging, and therapy monitoring in patients with transthyretin amyloid cardiomyopathy (ATTR-CM)?
Bone scintigraphy with SPECT and monoclonal protein exclusion remains the validated noninvasive diagnostic standard for ATTR-CM, while quantitative SPECT/CT and amyloid PET show promise for staging and therapy monitoring pending standardization and outcome validation.
Answers are grounded in this paper and cite their sources.
Bone scintigraphy retains high sensitivity for ATTR-CM; reinforces guideline-endorsed noninvasive diagnosis when monoclonal protein is excluded.
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an under-recognised cause of heart failure with preserved ejection fraction in older adults. The availability of disease-modifying therapies has made early and accurate identification, staging, and response assessment clinically important. Nuclear imaging occupies a central position in this pathway. To summarise the diagnostic accuracy, current clinical role, and emerging applications of bone-avid tracer scintigraphy, SPECT/CT quantification, and amyloid-targeted PET in the diagnosis, staging, and therapy monitoring of ATTR-CM. Methods: We performed a narrative review of published meta-analyses, single- and multicentre studies, consensus statements, and trial registrations identified through PubMed-indexed and open-access sources. Diagnostic estimates were extracted and are presented graphically. Results: In a meta-analysis of 39 publications (3,636 patients), bone scintigraphy had pooled sensitivity 0.97 and specificity 0.96 for ATTR-CM (AUC 0.99). Pooled sensitivities of 99mTc-DPD, 99mTc-PYP and 99mTc-HMDP were 0.98, 0.95 and 1.00. SPECT/CT improves specificity by separating myocardial from blood-pool activity; delayed SPECT/CT reached 100% sensitivity and 96.5% specificity in one series. PET with amyloid-binding tracers (11C-PiB, 18F-florbetapir, 18F-florbetaben, 18F-flutemetamol, 18F-NaF, 124I-evuzamitide) shows high sensitivity but heterogeneous specificity (pooled 0.98 and 0.61 in one meta-analysis of cardiac studies). Early quantitative SPECT/CT and dynamic PET studies show decreases in tracer uptake after tafamidis or eplontersen, although interpretation (stabilisation versus amyloid regression) and durability remain debated. Conclusions: Bone scintigraphy with SPECT and exclusion of a monoclonal protein is the validated, guideline-endorsed noninvasive diagnostic standard. Quantitative SPECT/CT and PET are promising for staging and monitoring but require standardisation and outcome validation before routine use.
No takes yet. Share an insight, caveat, or question.
Pakistan Journal of Medical & Cardiological Review (2026) conducted a review in Transthyretin amyloid cardiomyopathy (ATTR-CM). Bone-avid tracer scintigraphy, SPECT/CT quantification, and amyloid-targeted PET was evaluated on Diagnostic accuracy for ATTR-CM (Pooled sensitivity 0.97, specificity 0.96, AUC 0.99 for bone scintigraphy). Bone scintigraphy demonstrates 0.97 pooled sensitivity and 0.96 specificity for diagnosing ATTR-CM across 39 studies (3,636 patients).
Synapse has enriched 10 related papers. Consider them for comparative context: